Page 97 - 16Neonatal Jaundice_compressed
P. 97

Neonatal jaundice





                         Recommendations
                         See the end of Section 4.2.

                         Effectiveness of DAT
                         Description of included studies

                         For the effectiveness analysis, two studies 50;51  comparing selective versus universal DAT and a
                                  49
                         third study  comparing readmission rates and phototherapy rates for tested and untested babies
                         were included.
                         Review findings

                                                                    49
                         A retrospective observational study from the USA  studied the effectiveness of DAT testing in a
                         sample of births within a  1 year  period  (January to  December  2000). Mean  gestational age,
                         mean birthweight and gender were not specified; 46% of babies studied were Asian and 36.8%
                         were white. Cord blood DAT was performed on 2443 babies of mothers with blood group O or
                         Rhesus negative while 2097 babies of mothers with groups A, B, AB or Rhesus positive were
                         not tested. The records of all DAT-positive babies were reviewed for information relating to the
                         presence of jaundice and serum bilirubin results if measured in the first 24–48 hours. DAT was
                         positive in 193 (7.9%) of tested babies. Phototherapy was used in 36 (18.6%) of DAT-positive
                         babies. Data for use of phototherapy in DAT-negative babies were not provided. Readmission
                         for phototherapy  was needed for 26 (1.1%) of all DAT-tested babies, and for 19 (0.9%)  of
                         untested babies. This difference was not statistically significant (OR 1.17, 95% CI 0.65 to 2.13).
                         [EL III]

                                                                   51
                         A cohort study from a tertiary centre in the USA  compared universal with selective newborn
                         cord blood testing. In the retrospective cohort group, all cord blood specimens received by the
                         blood bank in  1989  were  tested while  in the prospective cohort group selective testing (all
                         babies in intensive care, babies with clinical jaundice, babies of Rhesus-negative mothers and/or
                         positive maternal antibody screening, maternal blood group unknown)  was carried out on
                         admissions between July 1990 and June 1991. Of the retrospective cohort,  2253  of  4003
                         eligible babies (56.3%) were tested. Of the prospective cohort, 1048 of 4498 babies (23.3%)
                         were tested selectively. Cord blood collection difficulties and specimen handling problems were
                         given  as  reasons  for  the  1750  missing  test  results  in  the  retrospective  sample.  Fifteen  babies
                         were readmitted for hyperbilirubinaemia in both study periods. The prevalence of DAT positive
                         tests was not specified. The rate of readmission for hyperbilirubinaemia was 0.4% (15 of 4003)
                         among universally tested babies and 0.3% (15 of 4498) among selectively tested babies. This
                         difference was not statistically significant (OR 1.12, 95% CI 0.56 to 2.30). [EL III]
                                                 50
                         A third study from the USA  also examined the effectiveness of universal versus selective DAT
                         testing.  A  retrospective  analysis  of  all  records  for  1990  and  1991  was  carried  out  to  identify
                         babies of group O, Rhesus-positive mothers. Altogether, 301 babies with a mean gestational age
                         of 39.4 weeks and mean birthweight of 3343.6 g were included; 50.5% were male, 44.5% were
                         white and 16.3% were black. Of 113 babies tested, 29 (26%) were ABO incompatible and 14
                         (12%) were DAT positive. A total of 188 babies were not tested routinely. Of these, 34 (18%)
                         had  DAT  tests  requested  by  their  treating  doctor;  18  (9.6%  were  ABO  incompatible  and  13
                         (6.9%)  were DAT positive. The overall prevalence  of DAT positivity  was  9.0%  (27  of 301
                         babies). Phototherapy was used in four of 113 universally tested babies (3.5%) and eight of 188
                         selectively tested babies (4.3%). The OR  was 0.83 (95% CI:  0.24 to 2.81).  The rate of
                         readmission for phototherapy was 1.8% (two of 113) among universally tested babies and 0.5%
                         (one of 188).  Again, this difference was not  statistically significant (OR 1.12, 95% CI 0.56 to
                         2.30). [EL III]
                         Evidence summary

                         Three EL III  studies using  undefined criteria for readmission for hyperbilirubinaemia were
                         included. Two studies compared universal versus selective DAT testing and one compared
                         DAT-tested and  DAT-untested cohorts.  No statistically  significant difference was found in the
                         readmission rates or phototherapy rates between those undergoing universal testing and those



              68
   92   93   94   95   96   97   98   99   100   101   102